MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
about
MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MAPK1E322K mutation increases ...... ced secretion of amphiregulin.
@en
MAPK1E322K mutation increases ...... ced secretion of amphiregulin.
@nl
type
label
MAPK1E322K mutation increases ...... ced secretion of amphiregulin.
@en
MAPK1E322K mutation increases ...... ced secretion of amphiregulin.
@nl
prefLabel
MAPK1E322K mutation increases ...... ced secretion of amphiregulin.
@en
MAPK1E322K mutation increases ...... ced secretion of amphiregulin.
@nl
P2093
P2860
P356
P1433
P1476
MAPK1E322K mutation increases ...... ced secretion of amphiregulin.
@en
P2093
Ann Marie Egloff
Kelsey P Pendleton
Vivian W Y Lui
Weiping Wen
P2860
P304
23300-23311
P356
10.18632/ONCOTARGET.8188
P407
P577
2016-03-18T00:00:00Z